PTJ
BCRX icon

Paul Tudor Jones’s BioCryst Pharmaceuticals BCRX Stock Holding History

Paul Tudor Jones’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$899K Sell
89,900
-5,800
-6% -$52.4K ﹤0.01% 2488
2026
Q1 		$911K Buy
+95,700
New +$743K ﹤0.01% 2439

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Paul Tudor Jones's BCRX Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 195,128 shares worth $1.95M. The stake represents ﹤0.01% of the portfolio and ranks #1961 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in BCRX as recently as Q4 2025.

Paul Tudor Jones first reported a position in BCRX in Q2 2015 and has held it in 27 quarters since. 316 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Paul Tudor Jones held 195,128 shares of BioCryst Pharmaceuticals worth $1.95M as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Paul Tudor Jones position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1961 holding.
  • Paul Tudor Jones first reported a position in BioCryst Pharmaceuticals in Q2 2015 and has held it in 27 quarters since.
  • 316 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.